A PROSPECTIVE STUDY ON DRUG UTILISATION AND EVALUATION OF ANTI-RETROVIRAL THERAPY AND ANTI-TUBERCULOSIS TREATMENT IN A TERTIARY CARE HOSPITAL

Main Article Content

SHAIK MOHAMMED SUHAIL
DIVYA KANDIPALLI
. LAKSHMI
ASHOK C. KUMAR
M. VENU MADHAV REDDY
M. PRAHARSHA LAKSHMI
P. SAMUEL CHANDRA

Abstract

Acquired immune deficiency syndrome is the most serious consequence of infection due to HIV which is a major health problem in public. India is with one sixth of world’s population where one of every eight people is HIV infected. Worldwide, tuberculosis is the common serious infection in HIV infected people. WHO estimated that 13% of 8.7 million individuals who develop incidence tuberculosis are co-infected with HIV. The research followed Prospective Observational Study of Anti-retroviral drugs and Anti-tubercular drugs. The total number of drugs for HIV and TB, were collected from inpatient records, as per the prescription, dose, and route of administration. The study involves the above 18 years old patients and it is planned over 6 months of period in ART CENTER. The demographic data and patient characteristics affected with HIV/AIDS and TB group were enrolled in the study. The analysis of study includes, a total number of 220 prescriptions during the research involving 152 males and 52 females and 16 other patients. The drug utility and evaluation for HIV and TB patients were with ART and ATT and with other poly-pharmacy to improve the immune system that is most important in HIV and TB.

Keywords:
HIV, tuberculosis, anti-retroviral therapy, anti-tuberculosis treatment, CD4 cells, drug utilization evaluation (DUE), drug utilization review (DUR), drug-drug interactions (DDI), drug related problems (DRPS), Drug therapy management (DTM)

Article Details

How to Cite
SUHAIL, S. M., KANDIPALLI, D., LAKSHMI, ., KUMAR, A. C., REDDY, M. V. M., LAKSHMI, M. P., & CHANDRA, P. S. (2022). A PROSPECTIVE STUDY ON DRUG UTILISATION AND EVALUATION OF ANTI-RETROVIRAL THERAPY AND ANTI-TUBERCULOSIS TREATMENT IN A TERTIARY CARE HOSPITAL. Journal of Disease and Global Health, 15(1), 9-17. Retrieved from https://ikppress.org/index.php/JODAGH/article/view/7650
Section
Data Articles

References

R Ministério da Saúde. Secretarial de Vigilance em Saúde. Departamento de Vigilância epidemiological. ProgramNational de Controlee da Tuberculosis. Not atechnicalsober as mudanças no treatment da tuberculosis no Brazil para-adult’s e adolescents - verso 2. Brasília: Ministério da Saúde; 2009.

Conde MB, Melo FA, Marques AM, Cardoso NC, Pinheiro VG, Dalcin Pie T, et al. III Brazilian Thoracic Association Guidelines on tuberculosis. J Bras Pneumol. 2009;35(10): 1018-48.

ONSUIDA. le poin surl epidemic Du Sida Geneva ONSUIDA; 2015.

Leclercq P, Roudiere L Viard J. Complications graver der treatments antiretroviralx reanimation Raviglione. 2004;13:230-2.

Blanc F, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-1infected adults with tuberculosis. New England Journal of Medicine. 2011;365:1471- 8.

Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.New England Journal of Medicine. 2011;365:1482-91.

Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculosis meningitis. Clin Infect.

Bieniasz PD. Intrinsic immunity: A front-line defines against viral attack. Nat Immunol. 2004; 5:1109–15.

Ravigilone M.sulis G tuberculosis 2015 Burdin, challenges and strategy for control and elimination infect Dis Rep. 2016; 8;6570.

Mqarlens G. Wikinsons Rj tuberculosis Lancet. 2007;370;2030-43.

World health organisation 2015 global tuberculosis report Geneva,Switzerland Wltol 2015.

World Health Organization (WHO) Global Tuberculosis Report 2013. Geneva; 2013.

Ho D, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M.. Rapid turnover of plasma virions and CD4 lymphocytes inHIV-1 infection. Nature. 1995;373:123.

Coffin JM, Hughes SH, Varmus HE, editors. Retroviruses. Plainview, NY USA: Cold Spring Harbor Laboratory Press; 1997.

Balabanian K, Harriague J, Decrion C, et al. CXCR4-tropic HIV-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary CD4+ T lymphocytes. J Immunol. 2004;173:7150–60.

Ray N, Doms RW. HIV-1 co receptors and their inhibitors. Curr Top Microbiol Immunol. 2006;30.

Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem. 2001;70:777–810

Platt EJ, Durnin JP, Kabat D. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Viral. 2005;79:4347–56.

Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol. 2003;21:265–304.

Schindler M, Muench J, Kutsch O, et al. Nef mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1 Cell. 2006;125:1055–67.

The Society of Hospital Pharmacists of Australia. The Committee of Specialty Practice in Drug Use Evaluation. SHPA standards of practice for drug use evaluation in Australian hospitals. Aust. J. Hosp. Pharm. 1996;26:240-6.

Bartlett JG, Gallant JE. 2000-2001 Medical Management of HIV Infection. Baltimore: Port City Press; 2000.

Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep. 2001; 50:1-57.